Drug combo shows promise for tough cancers

NCT ID NCT02856425

Completed Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jan 22, 2026 · Last updated Jun 10, 2026 · Updated 21 times

Summary

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nintedanib when given with pembrolizumab. The study aimed to see if this combination could be better tolerated and more effective than either drug alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH ANY ADVANCED SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Centre Léon Bérard

Lyon, 69008, France
Gustave Roussy

Villejuif, Val De Marne, 94805, France
Hôpital Bichat

Paris, 75018, France
IUCT--O

Toulouse, 31059, France
Institut Bergonié

Bordeaux, 33000, France

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH ANY ADVANCED SOLID TUMORS